Trial · NCT03044353
Results by group1,555
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,555
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Session 2, Day 24, n=6,0 | 2.505 | Standard Deviation 19.9174 | Grams |
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Session 3, Day 24, n=6,0 | 4.175 | Standard Deviation 22.9366 | Grams |
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Session 4, Day 24, n=5,0 | 9.194 | Standard Deviation 14.4271 | Grams |
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Session 5, Day 24, n=4,0 | 7.955 | Standard Deviation 19.4341 | Grams |
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | 8 Weeks Follow up, n=6,1 | 0.977 | Standard Deviation 12.1795 | Grams |
| Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up | Group 2: Post-chemotherapy AL Amyloidosis Participants | 8 Weeks Follow up, n=6,1 | -32.420 | Standard Deviation NA | Grams |
| Number of Participants With Any On-treatment Adverse Events (AEs) | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | 6 | Participants | ||
| Number of Participants With Any On-treatment Adverse Events (AEs) | Group 2: Post-chemotherapy AL Amyloidosis Participants | 1 | Participants | ||
| Number of Participants With Any Serious Adverse Events (SAEs) | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | 2 | Participants | ||
| Number of Participants With Any Serious Adverse Events (SAEs) | Group 2: Post-chemotherapy AL Amyloidosis Participants | 1 | Participants | ||
| Number of Participants With Abnormal Hematology Values | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Basophils, high | 2 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 2: Post-chemotherapy AL Amyloidosis Participants | Basophils, high | 0 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Basophils, normal | 4 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 2: Post-chemotherapy AL Amyloidosis Participants | Basophils, normal | 1 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Basophils, low | 0 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 2: Post-chemotherapy AL Amyloidosis Participants | Basophils, low | 0 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Eosinophils, high | 3 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 2: Post-chemotherapy AL Amyloidosis Participants | Eosinophils, high | 0 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 1: Cardiac TTR Amyloidosis (ATTR-CM) Participants | Eosinophils, normal | 3 | Participants | |
| Number of Participants With Abnormal Hematology Values | Group 2: Post-chemotherapy AL Amyloidosis Participants | Eosinophils, normal | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03044353/results